Mielo- i immunotropowe właściwości hormonów grasiczych – zastosowanie kliniczne w hematologii i onkologii


Author(s): Aleksander B Skotnicki

The concept of using the thymominetic drugs in haematology and oncology is based on growing body of evidence of the role of thymus and its hormones in control of immune reactivity. Thymic hormones take part in the immune reaction against several pathogens and are important in recognition and immune attack towards cancer cells expressing neoantigens. The present article describes the results of both experimental and clinical studies of calf thymus extract purified and produced in Poland as Thymus Factor X(TFX)* since 1976. TFX express typical activities of thymic hormones and was found to reveal the therapeutic effectiveness in patients with bone marrow insufficiencies of different origin as well as in patients with several malignant diseases improving their clinical status and prolonging survival. Apart from the results of obtained by Polish authors with TFX the article presents also similar observations performed by American, European and Chinese researchers with other thymominetic preparations.

Share this article

Editors List

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)

  • Skowronska-Gardas

    Department of Radiotherapy, Oncology Center-Institute (Warsaw, Poland)

  • Serban-Dan Costa

    Head of the Obstetrics and Gynecology Clinic of the University of Otto von Guericke (Magdeburg, Germany)